Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis

A. Crilly, S. Kolta, M. Dougados, R.D. Sturrock, B. Amor, H.A. Capell, R. Madhok

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To investigate the effect of cyclosporin A (CyA) therapy on circulating concentrations of interleukin-6 (IL-6) and soluble interleukin-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).

METHODS: Twenty four RA patients with active disease were studied. Plasma was collected before and after 16 weeks of CyA treatment. IL-6 was measured by B9 bioassay and sIL-2R by enzyme linked immunosorbent assay (ELISA).

RESULTS: The initial median IL-6 concentration of 165 IU/ml decreased significantly to 71 IU/ml after 16 weeks (p < 0.05). Similarly, the initial median plasma sIL-2R value of 665 U/ml decreased significantly to 570 U/ml (p < 0.05). This decrease was accompanied by an improvement in clinical parameters of disease activity. Some association between sIL-2R, IL-6, haemoglobin, and platelets was also observed.

CONCLUSIONS: This study has demonstrated that, in vivo, CyA therapy in RA can significantly reduce circulating concentrations of IL-6 and sIL-2R. Modulation of both T and non-T cell derived cytokines may be one mechanism by which CyA improves rheumatoid disease. Whether this is a direct effect of CyA on the cells within the rheumatoid joint producing these cytokines or an indirect effect mediated by other cytokines which can influence IL-6 and Il-2R values remains to be determined.

Original languageEnglish
Pages (from-to)137-9
Number of pages3
JournalAnnals of the Rheumatic Diseases
Volume54
Issue number2
DOIs
Publication statusPublished - Feb 1995
Externally publishedYes

Fingerprint

Interleukin-2 Receptors
Cyclosporine
Interleukin-6
Rheumatoid Arthritis
Cytokines
Plasmas
Immunosorbents
Bioassay
Platelets
Biological Assay
Assays
Hemoglobins
Therapeutics
Blood Platelets
Joints
Enzyme-Linked Immunosorbent Assay
Cells
Modulation
Association reactions
Enzymes

Keywords

  • Adult
  • Aged
  • Arthritis, Rheumatoid
  • Cyclosporine
  • Female
  • Hemoglobins
  • Humans
  • Interleukin-6
  • Male
  • Middle Aged
  • Platelet Count
  • Prospective Studies
  • Receptors, Interleukin-2

Cite this

Crilly, A. ; Kolta, S. ; Dougados, M. ; Sturrock, R.D. ; Amor, B. ; Capell, H.A. ; Madhok, R. / Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis. In: Annals of the Rheumatic Diseases. 1995 ; Vol. 54, No. 2. pp. 137-9.
@article{7427e8fe238a4a71aa4ae6d23206a316,
title = "Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis",
abstract = "OBJECTIVE: To investigate the effect of cyclosporin A (CyA) therapy on circulating concentrations of interleukin-6 (IL-6) and soluble interleukin-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).METHODS: Twenty four RA patients with active disease were studied. Plasma was collected before and after 16 weeks of CyA treatment. IL-6 was measured by B9 bioassay and sIL-2R by enzyme linked immunosorbent assay (ELISA).RESULTS: The initial median IL-6 concentration of 165 IU/ml decreased significantly to 71 IU/ml after 16 weeks (p < 0.05). Similarly, the initial median plasma sIL-2R value of 665 U/ml decreased significantly to 570 U/ml (p < 0.05). This decrease was accompanied by an improvement in clinical parameters of disease activity. Some association between sIL-2R, IL-6, haemoglobin, and platelets was also observed.CONCLUSIONS: This study has demonstrated that, in vivo, CyA therapy in RA can significantly reduce circulating concentrations of IL-6 and sIL-2R. Modulation of both T and non-T cell derived cytokines may be one mechanism by which CyA improves rheumatoid disease. Whether this is a direct effect of CyA on the cells within the rheumatoid joint producing these cytokines or an indirect effect mediated by other cytokines which can influence IL-6 and Il-2R values remains to be determined.",
keywords = "Adult, Aged, Arthritis, Rheumatoid, Cyclosporine, Female, Hemoglobins, Humans, Interleukin-6, Male, Middle Aged, Platelet Count, Prospective Studies, Receptors, Interleukin-2",
author = "A. Crilly and S. Kolta and M. Dougados and R.D. Sturrock and B. Amor and H.A. Capell and R. Madhok",
year = "1995",
month = "2",
doi = "10.1136/ard.54.2.137",
language = "English",
volume = "54",
pages = "137--9",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "2",

}

Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis. / Crilly, A.; Kolta, S.; Dougados, M.; Sturrock, R.D.; Amor, B.; Capell, H.A.; Madhok, R.

In: Annals of the Rheumatic Diseases, Vol. 54, No. 2, 02.1995, p. 137-9.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of cyclosporin A on interleukin-6 and soluble interleukin-2 receptor in patients with rheumatoid arthritis

AU - Crilly, A.

AU - Kolta, S.

AU - Dougados, M.

AU - Sturrock, R.D.

AU - Amor, B.

AU - Capell, H.A.

AU - Madhok, R.

PY - 1995/2

Y1 - 1995/2

N2 - OBJECTIVE: To investigate the effect of cyclosporin A (CyA) therapy on circulating concentrations of interleukin-6 (IL-6) and soluble interleukin-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).METHODS: Twenty four RA patients with active disease were studied. Plasma was collected before and after 16 weeks of CyA treatment. IL-6 was measured by B9 bioassay and sIL-2R by enzyme linked immunosorbent assay (ELISA).RESULTS: The initial median IL-6 concentration of 165 IU/ml decreased significantly to 71 IU/ml after 16 weeks (p < 0.05). Similarly, the initial median plasma sIL-2R value of 665 U/ml decreased significantly to 570 U/ml (p < 0.05). This decrease was accompanied by an improvement in clinical parameters of disease activity. Some association between sIL-2R, IL-6, haemoglobin, and platelets was also observed.CONCLUSIONS: This study has demonstrated that, in vivo, CyA therapy in RA can significantly reduce circulating concentrations of IL-6 and sIL-2R. Modulation of both T and non-T cell derived cytokines may be one mechanism by which CyA improves rheumatoid disease. Whether this is a direct effect of CyA on the cells within the rheumatoid joint producing these cytokines or an indirect effect mediated by other cytokines which can influence IL-6 and Il-2R values remains to be determined.

AB - OBJECTIVE: To investigate the effect of cyclosporin A (CyA) therapy on circulating concentrations of interleukin-6 (IL-6) and soluble interleukin-2 receptor (sIL-2R) in patients with rheumatoid arthritis (RA).METHODS: Twenty four RA patients with active disease were studied. Plasma was collected before and after 16 weeks of CyA treatment. IL-6 was measured by B9 bioassay and sIL-2R by enzyme linked immunosorbent assay (ELISA).RESULTS: The initial median IL-6 concentration of 165 IU/ml decreased significantly to 71 IU/ml after 16 weeks (p < 0.05). Similarly, the initial median plasma sIL-2R value of 665 U/ml decreased significantly to 570 U/ml (p < 0.05). This decrease was accompanied by an improvement in clinical parameters of disease activity. Some association between sIL-2R, IL-6, haemoglobin, and platelets was also observed.CONCLUSIONS: This study has demonstrated that, in vivo, CyA therapy in RA can significantly reduce circulating concentrations of IL-6 and sIL-2R. Modulation of both T and non-T cell derived cytokines may be one mechanism by which CyA improves rheumatoid disease. Whether this is a direct effect of CyA on the cells within the rheumatoid joint producing these cytokines or an indirect effect mediated by other cytokines which can influence IL-6 and Il-2R values remains to be determined.

KW - Adult

KW - Aged

KW - Arthritis, Rheumatoid

KW - Cyclosporine

KW - Female

KW - Hemoglobins

KW - Humans

KW - Interleukin-6

KW - Male

KW - Middle Aged

KW - Platelet Count

KW - Prospective Studies

KW - Receptors, Interleukin-2

U2 - 10.1136/ard.54.2.137

DO - 10.1136/ard.54.2.137

M3 - Article

VL - 54

SP - 137

EP - 139

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 2

ER -